Dr Oz says pharma investment shifting to US under Trump push
Synopsis
Dr Mehmet Oz says the Trump administration's drug-pricing deals and pro-innovation tilt are already pulling pharma capital, plants and even European talent into the United States. He cites ribbon-cuttings in Charlottesville and upgrades in Cincinnati as proof that the onshoring bet is moving from announcement to construction.
Key Takeaways
Dr Mehmet Oz , CMS Administrator, said pharma investment is shifting to the US at a White House briefing on 3 June .
He linked the trend to Trump administration drug-pricing deals and a pro-innovation policy stance.
Oz cited a recent ribbon-cutting in Charlottesville and an upgrade at a Cincinnati facility visited with President Trump .
He claimed a brain drain from Europe is helping fuel US pharma hiring.
The US remains the world's largest pharma market, though much of the API and generics supply chain sits offshore.
Centers for Medicare and Medicaid Services (CMS) Administrator Dr Mehmet Oz on Tuesday, 3 June said pharmaceutical companies are increasingly channelling investment into the United States, as the Trump administration presses ahead with its drive to expand domestic drug manufacturing. Speaking at a White House briefing in Washington, Oz argued that recent drug-pricing agreements and a pro-innovation policy stance are pulling capital, jobs and talent toward American shores.
What Dr Oz said
“There is a lot of investment coming to America,” Oz told reporters, responding to a question on when Americans would see results from manufacturing projects announced by drugmakers that recently struck pricing deals with the administration. He insisted the build-out is already underway, adding, “The jobs are starting. When the first time you hire someone to build a plan for you, we have a job.”
Why the US is gaining appeal
Oz framed the United States as an increasingly attractive base for research, development and production. “If you're a pharma executive, and America is open for business, and we're trying to support innovation, you know, saving people from cancer, autoimmune problems, dementia, all these different — you want to be where the action is,” he said. He also flagged what he described as a global talent shift, noting, “There's actually a brain drain from Europe in particular, but other parts of the world as well, if companies want to come here.”
Projects on the ground
The CMS chief cited recent site visits to underline the pace of activity, referencing a ribbon-cutting in Charlottesville and an existing facility in Cincinnati that he toured with President Donald Trump a few months ago. “They're already in, they've already have the facility, they're already running the facility, they're making additional investments to upgrade their program,” Oz said, adding that some plants are under construction while others are being expanded.
Pricing deals and the broader strategy
The remarks come as the administration promotes a wider healthcare and economic playbook that bundles lower prescription drug prices, expanded domestic production and a push to fortify pharmaceutical supply chains. Earlier in the briefing, Oz defended the pricing agreements with major drugmakers, arguing that cheaper medicines for American consumers can coexist with rising US capital expenditure. He said the approach aims to nurture innovation while ensuring Americans do not pay significantly more for medicines than patients abroad.
The bigger picture
The United States remains the world's largest pharmaceutical market and a leading hub for drug R&D. However, a substantial share of the global supply chain for active pharmaceutical ingredients and generic medicines still sits outside the country — a vulnerability the administration has repeatedly cited as it courts onshore investment. The coming quarters will test whether announced commitments translate into operational plants and durable employment.
Point of View
Site visits, executive sentiment — rather than verifiable capex numbers or job counts. The structural question is whether pricing concessions actually pencil out alongside multi-billion-dollar US plant builds, or whether companies front-load announcements while quietly maintaining offshore API dependence. A genuine onshoring shift will show up in FDA facility registrations and generics supply data, not press-briefing soundbites. Until then, the 'brain drain from Europe' framing is more political narrative than measurable migration.
NationPress
20 Jul 2026
Frequently Asked Questions
What did Dr Mehmet Oz say about pharma investment in the US?
Dr Mehmet Oz, the CMS Administrator, said on 3 June that pharmaceutical companies are increasingly investing in the United States as the Trump administration pushes domestic drug manufacturing. He said new hiring and plant construction are already underway.
Why is the Trump administration pushing domestic pharma manufacturing?
The administration argues that critical industries, including pharmaceuticals, should expand US production to reduce dependence on overseas supply chains. It has paired this with drug-pricing deals aimed at lowering costs for American consumers.
Which US facilities did Dr Oz cite as examples?
Oz referenced a recent ribbon-cutting at a pharmaceutical facility in Charlottesville and an existing plant in Cincinnati that he visited with President Donald Trump. He said the Cincinnati facility is making additional upgrades.
How do drug-pricing deals fit with higher US manufacturing investment?
Oz argued that lower prices for American consumers can coexist with greater investment in US production. He said the strategy seeks to support innovation while ensuring Americans do not pay significantly more for medicines than patients in other countries.
Is there evidence of a pharma 'brain drain' from Europe to the US?
Oz claimed there is a brain drain from Europe and other regions toward the United States as companies expand US operations. He did not cite specific data, and independent verification of the scale of any such talent shift is limited.
